BACKGROUND: Viral infection can exacerbate asthma by inducing the accumulation of inflammatory cells in the airway. We have previously reported that double-stranded RNA (dsRNA), a viral product and ligand of the Toll-like receptor-3 (TLR3), activates the transcription factors NF-κB and IRF-3 and upregulates the expression of inflammatory chemokines in airway epithelial cells. Here, we examined the effects of the glucocorticoid fluticasone propionate (FP) on the expression of the inflammatory chemokines CCL5, CXCL8 and CXCL10. METHODS: The airway epithelial cell line BEAS-2B was used for this study. Expression of CCL5, CXCL8 and CXCL10 mRNA and protein was quantified by real-time PCR and ELISA assay, respectively. To examine the association of FP with the physiology of chemokine production, we included several methods. Nuclear translocation of transcription factors was determined by performing Western blot analysis. Histone deacetylase (HDAC) activity in nuclear extracts was measured using a colorimetric assay. Stability of the chemokine mRNAs was examined in cells incubated with actinomycin D. The activities of the CCL5 promoter and the transcription factors NF-κB and IRF-3 were assessed using luciferase reporter assays. RESULTS: Treatment of BEAS-2B cells with FP significantly and dose-dependently (10(-9) to 10(-6)M) inhibited dsRNA-induced expression of CCL5, CXCL8 and CXCL10 protein and mRNA, but did not affect mRNA stability. FP also significantly inhibited dsRNA-stimulated CCL5 promoter activity. However, FP had no effect on the activity of HDAC or the nuclear translocation of NF-κB and IRF-3. CONCLUSIONS: FP inhibits the dsRNA-stimulated expression of inflammatory chemokines in airway epithelial cells. FP may act by inhibiting chemokine transcription through an as yet unidentified mechanism.
BACKGROUND:Viral infection can exacerbate asthma by inducing the accumulation of inflammatory cells in the airway. We have previously reported that double-stranded RNA (dsRNA), a viral product and ligand of the Toll-like receptor-3 (TLR3), activates the transcription factors NF-κB and IRF-3 and upregulates the expression of inflammatory chemokines in airway epithelial cells. Here, we examined the effects of the glucocorticoid fluticasone propionate (FP) on the expression of the inflammatory chemokines CCL5, CXCL8 and CXCL10. METHODS: The airway epithelial cell line BEAS-2B was used for this study. Expression of CCL5, CXCL8 and CXCL10 mRNA and protein was quantified by real-time PCR and ELISA assay, respectively. To examine the association of FP with the physiology of chemokine production, we included several methods. Nuclear translocation of transcription factors was determined by performing Western blot analysis. Histone deacetylase (HDAC) activity in nuclear extracts was measured using a colorimetric assay. Stability of the chemokine mRNAs was examined in cells incubated with actinomycin D. The activities of the CCL5 promoter and the transcription factors NF-κB and IRF-3 were assessed using luciferase reporter assays. RESULTS: Treatment of BEAS-2B cells with FP significantly and dose-dependently (10(-9) to 10(-6)M) inhibited dsRNA-induced expression of CCL5, CXCL8 and CXCL10 protein and mRNA, but did not affect mRNA stability. FP also significantly inhibited dsRNA-stimulated CCL5 promoter activity. However, FP had no effect on the activity of HDAC or the nuclear translocation of NF-κB and IRF-3. CONCLUSIONS: FP inhibits the dsRNA-stimulated expression of inflammatory chemokines in airway epithelial cells. FP may act by inhibiting chemokine transcription through an as yet unidentified mechanism.
Authors: S Matsukura; C Stellato; J R Plitt; C Bickel; K Miura; S N Georas; V Casolaro; R P Schleimer Journal: J Immunol Date: 1999-12-15 Impact factor: 5.422
Authors: K Grünberg; R F Sharon; J K Sont; J C In 't Veen; W A Van Schadewijk; E P De Klerk; C R Dick; J H Van Krieken; P J Sterk Journal: Am J Respir Crit Care Med Date: 2001-11-15 Impact factor: 21.405
Authors: S Matsukura; F Kokubu; H Kubo; T Tomita; H Tokunaga; M Kadokura; T Yamamoto; Y Kuroiwa; T Ohno; H Suzaki; M Adachi Journal: Am J Respir Cell Mol Biol Date: 1998-02 Impact factor: 6.914
Authors: Claire E McCoy; Susan Carpenter; Eva M Pålsson-McDermott; Linden J Gearing; Luke A J O'Neill Journal: J Biol Chem Date: 2008-03-20 Impact factor: 5.157
Authors: C L Skevaki; I Christodoulou; I S Spyridaki; I Tiniakou; V Georgiou; P Xepapadaki; D A Kafetzis; N G Papadopoulos Journal: Clin Exp Allergy Date: 2009-06-22 Impact factor: 5.018
Authors: Janet M Davies; Melanie L Carroll; Hongzhuo Li; Alisa M Poh; Darren Kirkegard; Michelle Towers; John W Upham Journal: PLoS One Date: 2011-11-18 Impact factor: 3.240
Authors: Tetsuya Homma; Atsushi Kato; Masafumi Sakashita; James E Norton; Lydia A Suh; Roderick G Carter; Robert P Schleimer Journal: Am J Respir Cell Mol Biol Date: 2015-04 Impact factor: 6.914
Authors: T M Darlington; R Pimentel; K Smith; A V Bakian; L Jerominski; J Cardon; N J Camp; W B Callor; T Grey; M Singleton; M Yandell; P F Renshaw; D A Yurgelun-Todd; D Gray; H Coon Journal: Transl Psychiatry Date: 2014-10-21 Impact factor: 6.222
Authors: Aran Singanayagam; Nicholas Glanville; Jason L Girkin; Yee Man Ching; Andrea Marcellini; James D Porter; Marie Toussaint; Ross P Walton; Lydia J Finney; Julia Aniscenko; Jie Zhu; Maria-Belen Trujillo-Torralbo; Maria Adelaide Calderazzo; Chris Grainge; Su-Ling Loo; Punnam Chander Veerati; Prabuddha S Pathinayake; Kristy S Nichol; Andrew T Reid; Phillip L James; Roberto Solari; Peter A B Wark; Darryl A Knight; Miriam F Moffatt; William O Cookson; Michael R Edwards; Patrick Mallia; Nathan W Bartlett; Sebastian L Johnston Journal: Nat Commun Date: 2018-06-08 Impact factor: 14.919
Authors: Kai Sen Tan; Rachel Liyu Lim; Jing Liu; Hsiao Hui Ong; Vivian Jiayi Tan; Hui Fang Lim; Kian Fan Chung; Ian M Adcock; Vincent T Chow; De Yun Wang Journal: Front Cell Dev Biol Date: 2020-02-25